FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

871701001: Sacituzumab govitecan (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2020. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3973908017 Sacituzumab govitecan en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3973909013 Sacituzumab govitecan (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Sacituzumab govitecan This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Topoisomerase inhibitor (disposition) true Inferred relationship Some
Sacituzumab govitecan Is a Topoisomerase inhibitor true Inferred relationship Some
Sacituzumab govitecan This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Sacituzumab false Inferred relationship Some
Sacituzumab govitecan Is a Monoclonal antibody true Inferred relationship Some
Sacituzumab govitecan Is a Enzyme inhibitor protein true Inferred relationship Some
Sacituzumab govitecan Is a Antineoplastic agent (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Sacituzumab govitecan-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Sacituzumab govitecan Inferred relationship Some 1
Sacituzumab govitecan only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Sacituzumab govitecan Inferred relationship Some 1
Product containing sacituzumab govitecan in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Sacituzumab govitecan Inferred relationship Some 1
Sacituzumab govitecan only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Sacituzumab govitecan Inferred relationship Some 1

This concept is not in any reference sets

Back to Start